Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
21 March 2014Website:
http://www.pulmatrix.comNext earnings report:
08 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 22:43:10 GMTDividend
Analysts recommendations
Institutional Ownership
PULM Latest News
Completed series of transactions with MannKind Corporation validating iSPERSE ™ technology and extending projected cash runway into Q4 2026 $12.4 million in cash and cash equivalents at the end of Q2 2024, with an additional $1.4 million in restricted cash becoming unrestricted in August 2024 Pursuing strategic alternatives to further leverage iSPERSE ™ and optimize the potential of PUR3100 FRAMINGHAM, Mass. , Aug. 13, 2024 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious central nervous system and pulmonary disease using its patented dry powder inhalation iSPERSE™ technology, today announced second quarter financial results for 2024 and provided a corporate update on its clinical assets.
Cross license involves Pulmatrix iSPERSE™ technology and MannKind's Cricket® inhalation device. Pulmatrix transferring leased building, all leasehold improvements, laboratory equipment and other related personal property in exchange for MannKind assumption of lease.
What type of business is Pulmatrix?
Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.
What sector is Pulmatrix in?
Pulmatrix is in the Healthcare sector
What industry is Pulmatrix in?
Pulmatrix is in the Biotechnology industry
What country is Pulmatrix from?
Pulmatrix is headquartered in United States
When did Pulmatrix go public?
Pulmatrix initial public offering (IPO) was on 21 March 2014
What is Pulmatrix website?
https://www.pulmatrix.com
Is Pulmatrix in the S&P 500?
No, Pulmatrix is not included in the S&P 500 index
Is Pulmatrix in the NASDAQ 100?
No, Pulmatrix is not included in the NASDAQ 100 index
Is Pulmatrix in the Dow Jones?
No, Pulmatrix is not included in the Dow Jones index
When was Pulmatrix the previous earnings report?
No data
When does Pulmatrix earnings report?
The next expected earnings date for Pulmatrix is 08 November 2024